181 related articles for article (PubMed ID: 10712432)
21. Pagetic osteoclasts formed in vitro: absence of paracrystalline inclusions.
Roodman GD; Ohsaki Y; Miller MM; Demulder A; Hosking D; Singer FR; McManus LM
J Submicrosc Cytol Pathol; 1998 Apr; 30(2):315-27. PubMed ID: 9648296
[TBL] [Abstract][Full Text] [Related]
22. Measles virus nucleocapsid protein, a key contributor to Paget's disease, increases IL-6 expression via down-regulation of FoxO3/Sirt1 signaling.
Wang FM; Sarmasik A; Hiruma Y; Sun Q; Sammut B; Windle JJ; Roodman GD; Galson DL
Bone; 2013 Mar; 53(1):269-76. PubMed ID: 23262029
[TBL] [Abstract][Full Text] [Related]
23. Atypical multinucleated cells form in long-term marrow cultures from patients with Paget's disease.
Kukita A; Chenu C; McManus LM; Mundy GR; Roodman GD
J Clin Invest; 1990 Apr; 85(4):1280-6. PubMed ID: 2318982
[TBL] [Abstract][Full Text] [Related]
24. Osteoclast-derived IGF1 induces RANKL production in osteocytes and contributes to pagetic lesion formation.
Miyagawa K; Tenshin H; Mulcrone PL; Delgado-Calle J; Subler MA; Windle JJ; Chirgwin JM; Roodman GD; Kurihara N
JCI Insight; 2023 Jul; 8(14):. PubMed ID: 37338990
[TBL] [Abstract][Full Text] [Related]
25. Measles virus nucleocapsid protein modulates the Signal Regulatory Protein-β1 (SIRPβ1) to enhance osteoclast differentiation in Paget's disease of bone.
Sundaram K; Sambandam Y; Shanmugarajan S; Rao DS; Reddy SV
Bone Rep; 2017 Dec; 7():26-32. PubMed ID: 28840181
[TBL] [Abstract][Full Text] [Related]
26. SOCS-1/3 participation in FGF-2 signaling to modulate RANK ligand expression in paget's disease of bone.
Sundaram K; Senn J; Reddy SV
J Cell Biochem; 2013 Sep; 114(9):2032-8. PubMed ID: 23553658
[TBL] [Abstract][Full Text] [Related]
27. Failure to detect measles virus ribonucleic acid in bone cells from patients with Paget's disease.
Matthews BG; Afzal MA; Minor PD; Bava U; Callon KE; Pitto RP; Cundy T; Cornish J; Reid IR; Naot D
J Clin Endocrinol Metab; 2008 Apr; 93(4):1398-401. PubMed ID: 18230662
[TBL] [Abstract][Full Text] [Related]
28. RANKing the importance of measles virus in Paget's disease.
Ross FP
J Clin Invest; 2000 Mar; 105(5):555-8. PubMed ID: 10712423
[No Abstract] [Full Text] [Related]
29. Vitamin D antagonist, TEI-9647, inhibits osteoclast formation induced by 1alpha,25-dihydroxyvitamin D3 from pagetic bone marrow cells.
Ishizuka S; Kurihara N; Miura D; Takenouchi K; Cornish J; Cundy T; Reddy SV; Roodman GD
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):331-4. PubMed ID: 15225795
[TBL] [Abstract][Full Text] [Related]
30. A novel mutation (K378X) in the sequestosome 1 gene associated with increased NF-kappaB signaling and Paget's disease of bone with a severe phenotype.
Rea SL; Walsh JP; Ward L; Yip K; Ward BK; Kent GN; Steer JH; Xu J; Ratajczak T
J Bone Miner Res; 2006 Jul; 21(7):1136-45. PubMed ID: 16813535
[TBL] [Abstract][Full Text] [Related]
31. Insights into the pathogenesis of Paget's disease.
Roodman GD
Ann N Y Acad Sci; 2010 Mar; 1192():176-80. PubMed ID: 20392234
[TBL] [Abstract][Full Text] [Related]
32. Cell biology of Paget's disease.
Reddy SV; Menaa C; Singer FR; Demulder A; Roodman GD
J Bone Miner Res; 1999 Oct; 14 Suppl 2():3-8. PubMed ID: 10510206
[TBL] [Abstract][Full Text] [Related]
33. The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma.
Ehrlich LA; Roodman GD
Immunol Rev; 2005 Dec; 208():252-66. PubMed ID: 16313353
[TBL] [Abstract][Full Text] [Related]
34. A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment.
Hiruma Y; Kurihara N; Subler MA; Zhou H; Boykin CS; Zhang H; Ishizuka S; Dempster DW; Roodman GD; Windle JJ
Hum Mol Genet; 2008 Dec; 17(23):3708-19. PubMed ID: 18765443
[TBL] [Abstract][Full Text] [Related]
35. Paget's disease-a VDR coactivator disease?
Kurihara N; Ishizuka S; Demulder A; Menaa C; Roodman GD
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):321-5. PubMed ID: 15225793
[TBL] [Abstract][Full Text] [Related]
36. A negative search for a paramyxoviral etiology of Paget's disease of bone: molecular, immunological, and ultrastructural studies in UK patients.
Helfrich MH; Hobson RP; Grabowski PS; Zurbriggen A; Cosby SL; Dickson GR; Fraser WD; Ooi CG; Selby PL; Crisp AJ; Wallace RG; Kahn S; Ralston SH
J Bone Miner Res; 2000 Dec; 15(12):2315-29. PubMed ID: 11127197
[TBL] [Abstract][Full Text] [Related]
37. Studies in Paget's disease and their relevance to oncology.
Roodman GD
Semin Oncol; 2001 Aug; 28(4 Suppl 11):15-21. PubMed ID: 11544571
[TBL] [Abstract][Full Text] [Related]
38. [Viral origin of Paget's disease of bone?].
Basle MF; Chappard D; Rebel A
Presse Med; 1996 Jan; 25(3):113-8. PubMed ID: 8746085
[TBL] [Abstract][Full Text] [Related]
39. Eosinophil chemotactic factor-L (ECF-L): a novel osteoclast stimulating factor.
Oba Y; Chung HY; Choi SJ; Roodman GD
J Bone Miner Res; 2003 Jul; 18(7):1332-41. PubMed ID: 12854845
[TBL] [Abstract][Full Text] [Related]
40. 1,25-Dihydroxyvitamin D3 hypersensitivity of osteoclast precursors from patients with Paget's disease.
Menaa C; Barsony J; Reddy SV; Cornish J; Cundy T; Roodman GD
J Bone Miner Res; 2000 Feb; 15(2):228-36. PubMed ID: 10703924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
